Coordinator : Pr. Maria José Alonso

This is a large-scale collaborative research project within the 7^th European Framework Program  for Research and Technological Development. The TRANS-INT project will run from May 1^st, 2012 to April 30^th, 2017.

 

In TRANS-INT a clear concept and shared ambition provide the cohesive force. The concept behind TRANS-INT is the rational design of oral nanomedicines based on safety, mechanistic, bioengineering and pharmaceutical technology criteria.

 

The consortium is composed of 16 partners from industry and academia with complementary leading expertise in chemistry, chemical engineering, pharmaceutical technology, molecular physiology, biopharmaceutics, toxicology and drug development.

 

TRANSINT combines expertise in pharmaceutical nanotechnology, biochemistry, immunology, toxicology, biology and physiology with the aim to develop a novel nanodrug candidate able to effectively fight diabetes. TRANSINT researchers will make use of nanotechnology to find new oral ways for drug delivery that can become an alternative to insulin injection, thus improving the quality of life of patients with diabetes.

 

more details...